CRH elects W. Anthony (Tony) Will to its Board of Directors June 16, 2026 CRH (NYSE: CRH), the leading provider of building materials, today announced the election of Mr. Tony Will, 60, to the CRH Board of Directors, effective July 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616955234/en/ “We are delighted to welcome Tony to our Board of Directors,” said Richie Boucher, CRH Chairman. [...]
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy June 16, 2026 Fund VIII Reflects Strong Global Investor Support for Clearlake’s Integrated Platform, Operational Value-Creation Model, and AI-Enabled Investment Approach
Moody’s Brings Its Decision-Grade Intelligence to Amazon Quick June 16, 2026 Moody’s Corporation (NYSE: MCO) today announced that its connected intelligence is now available in Amazon Quick – a personalized, proactive AI assistant – through a dedicated Model Context Protocol (MCP) server. The integration gives customers operating in Amazon Web Services (AWS) direct access to ratings and research from Moody’s Ratings, as well as Moody’s curated [...]
AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas June 16, 2026 vMiX™ is a vectorized RNA interference (RNAi) platform combining knockdown, cell-specific expression with the flexibility to target multiple genes Update follows recent positive AVB-406 preclinical data presented at ASGCT, supporting the broad therapeutic potential of the vMiX platform including initiation of clinical trials in 2026
Qualco Supports London’s Air Ambulance Charity as £1.5m Raised at Black & White Gala June 16, 2026 Qualco Group and the Qualco Foundation have announced their support for London’s Air Ambulance Charity, helping raise £1.5 million at the Black & White Gala, one of the capital’s most prominent fundraising events. The event, which is hosted every two years by the charity’s Philanthropy Board, took place this year on June 4, bringing together [...]
Optimum Asset Management’s Investor Summit in Portofino brings together Mike Pompeo, Matteo Renzi and leaders across government, finance and industry to discuss the future of the global economy and geopolitics June 16, 2026 Mike Pompeo addressed geopolitical risks including China, Iran, Ukraine and Europe-US security cooperation. Matteo Renzi, Edoardo Rixi and senior government representatives joined discussions on European competitiveness, infrastructure and energy. The summit convened institutional investors, entrepreneurs and financial market professionals to discuss the future of the global economy.
Usercentrics CMP and Cookiebot by Usercentrics Claim Extended G2 Leadership in Summer 2026 June 16, 2026 Cookiebot by Usercentrics Earns Enterprise Recognition for the First Time and Claims #1 in Cookie Tracking
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity June 16, 2026 ABB Robotics and PSYONIC collaborate to revolutionize grasping and dexterity, a core capability for Autonomous Versatile Robotics™ ABB GoFa™ helps test PSYONIC’s Ability Hand for robotics, combining touch sensing, compliant design and human-derived training data Dexterity remains a major challenge for industry; improved handling can reduce engineering time by up to 30%¹
cTAP Announces Novel Prognostic Score Developed for Duchenne Muscular Dystrophy Patients Offers Improved Prediction of Loss of Ambulation June 15, 2026 The Collaborative Trajectory Analysis Project (cTAP) announces the publication of a novel, validated prognostic score for predicting the loss of ambulation (LoA) in patients with Duchenne muscular dystrophy (DMD). According to research published May 26, 2026, in Neurology®, the medical journal of the American Academy of Neurology, this simple, easy-to-use score, based on two common [...]
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe June 15, 2026 Alkermes plc (Nasdaq: ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), was recently granted orphan drug designations (ODD) from leading regulatory bodies in the U.S. and Europe. The U.S. Food [...]